ALIMERA SCIENCES INC
ALIMHealthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | |
|---|---|---|---|---|---|---|
| Revenue | $80.8M | $54.1M | $59.0M | $50.8M | $53.9M | $46.6M |
| Operating income | −$1.9M | −$11.6M | −$201,000 | −$501,000 | −$5.3M | −$9.7M |
| Net income | −$20.1M | −$18.1M | −$4.4M | −$5.3M | −$10.4M | −$16.4M |
| Total assets | $153.5M | $42.6M | $58.5M | $50.9M | $50.3M | $54.1M |
| Total liabilities | $107.4M | $63.4M | — | — | — | — |
| Equity | $46.2M | −$20.8M | −$2.6M | −$8.0M | −$4.4M | $2.7M |
| EPS (diluted) | $-0.84 | $-2.59 | $-0.66 | — | $-2.19 | $3.71 |
| Shares out. | 7.2M | 7.0M | 5.8M | 5.0M | 71.0M | 70.0M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2023- Operating margin
- −2.4%
- Net margin
- −24.9%
- Return on equity
- −43.6%
- Return on assets
- −13.1%
- Return on capital (ROCE)
- −1.5%
- Liabilities / assets
- 69.9%
- Debt / equity
- 2.33×
- Book value / share
- $6.39
- Revenue growth (YoY)
- 49.2%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2023- Altman Z″ (distress)
- -7.22distress
- Accruals / assets
- −3.8%clean
- Piotroski F-Score
- 5/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 1 severe● 3 warning● 2 good- Altman Z″ in the distress zone
- Operating losses (negative operating margin)
- Reported a net loss
- Negative operating cash flow
- Revenue is growing year-over-year
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 4Active Not Recruitingreadout ~2024-12-31A Study of Intravitreal ILUVIEN® Implant as Baseline Therapy in Patients With Early Diabetic Macular Edema (DME)
- Phase 4Active Not Recruitingreadout ~2025-11Fluocinolone Acetonide Intravitreal Implant 0.18 mg in the Treatment of Chronic Non-Infectious Posterior Segment Uveitis
- Phase 4Recruitingreadout ~2026-07-15Open Label Trial Studying the Safety and Effectiveness of ILUVIEN® (190μg) in Children and Adolescents, Who Have Recurrent Non-infectious Uveitis Affecting the Posterior Segment of the Eye.
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Snisarenko JohnDirector | Sep 16, 2024 | D | 10,000 | — |
| Holland DavidOfficer — Chief Marketing Officer & SVP | Sep 16, 2024 | D | 187,756 | — |
| Eiswirth Richard S JrOfficer — President and CEO | Sep 16, 2024 | D | 324,018 | — |
| Pizzo Peter J. IiiDirector | Sep 16, 2024 | D | 500 | — |
| Werner Jason M.Officer — Chief Operating Officer | Sep 16, 2024 | D | 225,000 | — |
| Ashman PhilipOfficer — President of Int'l Operations | Sep 16, 2024 | D | 118,274 | — |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Material events
SEC Form 8-K · most recent- Terminated a material agreement · Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylaws · Other material eventSep 16, 2024
- Other material eventSep 11, 2024
- Director / officer change · Shareholder voteSep 10, 2024
- Other material eventSep 10, 2024
- Results of operationsAug 6, 2024
- Entered a material agreementJul 23, 2024
- Entered a material agreementJun 24, 2024
- Entered a material agreement · Regulation FD disclosure · Other material eventJun 24, 2024
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- SC 13G/ANov 13, 2024
- SC 13G/ANov 7, 2024
- 15-12GSep 26, 2024
- EFFECTSep 20, 2024
- EFFECTSep 20, 2024
- 4OWNERSHIP DOCUMENTSep 18, 2024
- 4OWNERSHIP DOCUMENTSep 18, 2024
- 4OWNERSHIP DOCUMENTSep 18, 2024
- 4OWNERSHIP DOCUMENTSep 18, 2024
- 4OWNERSHIP DOCUMENTSep 18, 2024
- 4OWNERSHIP DOCUMENTSep 18, 2024
- 4OWNERSHIP DOCUMENTSep 18, 2024
- 4OWNERSHIP DOCUMENTSep 18, 2024
- 4OWNERSHIP DOCUMENTSep 18, 2024
- 4OWNERSHIP DOCUMENTSep 18, 2024
Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.